Sermorelin (MR-409) and MIA-690 show anxiolytic and antidepressant-like effects in mice via anti-inflammatory pathways.
Background
Growth hormone-releasing hormone (GHRH) and its analogs are primarily known for their effects on growth hormone secretion and have been investigated for potent antitumor effects. However, their influence on central nervous system functions, particularly mood and behavior, remains largely unexplored. There is a significant need for novel therapeutic approaches for anxiety and depression, which are often linked to neuroinflammation and oxidative stress. This study investigates whether GHRH analogs, specifically the antagonist MIA-690 and agonist MR-409 (a sermorelin analog), can modulate these pathways in the brain, potentially offering a new mechanism for treating mood disorders.
Study Design
Researchers investigated the effects of a GHRH antagonist (MIA-690) and a GHRH agonist (MR-409, a sermorelin analog) on mouse models. The ex vivo portion involved treating isolated mouse prefrontal cortex specimens with lipopolysaccharide (LPS) to induce inflammation, followed by treatment with the GHRH analogs. The in vivo portion involved chronic treatment of mice with MR-409 at a dose of 5 µg/day for 4 weeks. The study assessed emotional behavior and analyzed gene expression of inflammatory and oxidative markers in the prefrontal cortex.
Results
Both GHRH analogs exerted significant anti-inflammatory and antioxidant effects. Ex vivo, both MIA-690 and MR-409 inhibited LPS-induced inflammatory and pro-oxidative markers. In vivo, both compounds induced anxiolytic and antidepressant-like effects. This was accompanied by increased levels of norepinephrine and serotonin in the prefrontal cortex. Gene expression of inflammatory markers like NF-kB, TNF-α, and IL-6 was decreased.
The study also found that MR-409 treatment for 4 weeks at 5 µg/day induced a downregulation of both gene and protein expression for the pituitary-type GHRH-receptor (
GHRH-R) in the prefrontal cortex of mice. Furthermore, the expression of the antioxidant-related transcription factorNrf2was increased in mice treated with both analogs. Notably, MIA-690 showed higher efficacy in inhibiting all tested inflammatory and oxidative markers compared to MR-409.
Key Findings
- Chronic in vivo treatment with GHRH agonist MR-409 (sermorelin analog) induced anxiolytic and antidepressant-like effects in mice.
- Both MR-409 and antagonist MIA-690 increased norepinephrine and serotonin levels in the mouse prefrontal cortex.
- Both analogs decreased gene expression of inflammatory markers NF-kB, TNF-α, and IL-6.
- MR-409 at 5 µg/day for 4 weeks caused a downregulation of GHRH-receptor gene and protein expression in the prefrontal cortex.
- GHRH antagonist MIA-690 showed higher efficacy than agonist MR-409 in inhibiting inflammatory and oxidative markers.
Why It Matters
These findings suggest that GHRH analogs like sermorelin may have beneficial effects on mood beyond their established roles, potentially by directly modulating neuroinflammation and monoamine neurotransmitter systems in the brain. For users, this introduces a novel, non-obvious application for GHRH agonists, linking them to mental well-being, anxiety reduction, and antidepressant-like activity. The downregulation of the GHRH-R in the prefrontal cortex after chronic use of MR-409 is a critical observation, suggesting receptor desensitization that could influence long-term dosing protocols. This study provides a mechanistic basis for exploring sermorelin and related peptides for mood disorders, though human clinical data is required to translate these preclinical animal findings into a usable protocol.
